These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20454855)

  • 1. Pharmacokinetics of methylphenidate following two oral formulations (immediate and sustained release) in the dog.
    Giorgi M; Prise U; Soldani G; Neri D; Lavy E
    Vet Res Commun; 2010 Jun; 34 Suppl 1():S73-7. PubMed ID: 20454855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of methylphenidate after oral administration of immediate and sustained-release preparations in Beagle dogs.
    Lavy E; Prise U; Soldani G; Neri D; Brandriss N; Bar Chaim A; Giorgi M
    Vet J; 2011 Sep; 189(3):336-40. PubMed ID: 20696604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension.
    Childress AC; Berry SA
    Postgrad Med; 2010 Sep; 122(5):35-41. PubMed ID: 20861586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose Pharmacokinetic Properties and Relative Bioavailability of a Novel Methylphenidate Extended-release Chewable Tablet Compared With Immediate-release Methylphenidate Chewable Tablet.
    Abbas R; Palumbo D; Walters F; Belden H; Berry SA
    Clin Ther; 2016 May; 38(5):1151-7. PubMed ID: 27021606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.
    Tuerck D; Wang Y; Maboudian M; Wang Y; Sedek G; Pommier F; Appel-Dingemanse S
    Int J Clin Pharmacol Ther; 2007 Dec; 45(12):662-8. PubMed ID: 18184535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers.
    Adjei A; Teuscher NS; Kupper RJ; Chang WW; Greenhill L; Newcorn JH; Connor DF; Wigal S
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):570-8. PubMed ID: 25514542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of food on the pharmacokinetics of methylphenidate.
    Midha KK; McKay G; Rawson MJ; Korchinski ED; Hubbard JW
    Pharm Res; 2001 Aug; 18(8):1185-9. PubMed ID: 11587491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylphenidate bioavailability from two extended-release formulations.
    González MA; Pentikis HS; Anderl N; Benedict MF; DeCory HH; Dirksen SJ; Hatch SJ
    Int J Clin Pharmacol Ther; 2002 Apr; 40(4):175-84. PubMed ID: 11996212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Gupta S; Heverin E; Starr HL
    J Child Adolesc Psychopharmacol; 2011 Jun; 21(3):255-63. PubMed ID: 21663428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria.
    Shram MJ; Quinn AM; Chen N; Faulknor J; Luong D; Sellers EM; Endrenyi L
    Clin Ther; 2012 May; 34(5):1170-81. PubMed ID: 22512898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative Bioavailability of Methylphenidate Extended-release Chewable Tablets Chewed Versus Swallowed Whole.
    Abbas R; Childress AC; Nagraj P; Rolke R; Berry SA; Palumbo DR
    Clin Ther; 2018 May; 40(5):733-740. PubMed ID: 29703430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of the Pharmacokinetics of Methylphenidate Extended-Release Orally Disintegrating Tablets With a Reference Extended-Release Formulation of Methylphenidate in Healthy Adults.
    Childress A; Stark JG; McMahen R; Engelking D; Sikes C
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):151-159. PubMed ID: 28544581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule.
    Rochdi M; González MA; Dirksen SJ
    Int J Clin Pharmacol Ther; 2004 May; 42(5):285-92. PubMed ID: 15176652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation.
    Modi NB; Lindemulder B; Gupta SK
    J Clin Pharmacol; 2000 Apr; 40(4):379-88. PubMed ID: 10761165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
    Quinn D; Wigal S; Swanson J; Hirsch S; Ottolini Y; Dariani M; Roffman M; Zeldis J; Cooper T
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1422-9. PubMed ID: 15502602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.